Therapy Areas: Cardiovascular
Ionis and AstraZeneca's eplontersen Phase 3 ATTR-CM trial misses primary endpoint, subgroup analysis shows nominal benefit
9 July 2026 - Biotechnology company Ionis Pharmaceuticals Inc (Nasdaq:IONS) and its partner AstraZeneca plc (STO:AZN) (LON:AZN) (NYSE:AZN) reported on Thursday that the Phase 3 CARDIO-TTRansform trial...
EQT to acquire biosurgery company Corza Biosurgery
7 July 2026 - Swedish private equity company EQT AB (STO: EQT) said on Tuesday it has agreed to acquire the specialist biologics business Corza Biosurgery from global medical technology company Corza ...
Cirius Therapeutics commences enrolment and dosing for Phase 2 study of CIR-0602K in type 1 diabetes
25 June 2026 - Cirius Therapeutics Inc, a developer of innovative therapies for people suffering from diseases caused by mitochondrial dysfunction and insulin resistance, announced on Wednesday that e...
Thalia Therapeutics acquires Sanmirna and raises GBP2.75m to advance AML RNA therapy
24 June 2026 - Biotechnology company Thalia Therapeutics plc (AIM: THAT) disclosed on Wednesday that it has agreed to acquire clinical-stage oncology company Sanmirna Therapeutics Inc, adding its lead...
Novo Nordisk Foundation funds European initiative to accelerate drug discovery for cardiometabolic diseases
22 June 2026 - The Novo Nordisk Foundation, a philanthropic enterprise foundation created by Danish pharmaceutical company Novo Nordisk A/S (CPH:NOVO-B) (NYSE:NVO), announced on Friday that it is fund...
Kalohexis presents dual MC3R/MC4R activation data at ENDO 2026
16 June 2026 - Clinical-stage biotechnology company Kalohexis Inc announced on Monday that data supporting dual melanocortin-3 receptor/melanocortin-4 receptor (MC3R/MC4R) activation as a novel mechan...